Biopharmaceuticals giant Merck said today that it is investing $90M in setting up a new, San Diego research organization, called Calibr. According to Merck, the new, independent not-for-profit will aim to accelerate translation of basic biomedical research into new medicines to treat disease, and will be led by Peter G. Schultz, Ph.D. z is a professor at The Scripps Research Institute. Merck said it will provide funding to Calibr of up to $90M over a period of seven years, and will retain an option to obtain an exclusive, commercial license to proteins or small molecule therapeutic candidates derived from work conducted by Calibr.
Top NewsThursday, March 15, 2012
Merck Invests $90M In San Diego Research Group